ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2017, at 5:00 p.m. Eastern Time
SAN DIEGO–(BUSINESS WIRE)–Aug. 1, 2017– ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, August 8, 2017, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for participants in the United States or Canada and 830-865-2550 for international callers (reference passcode 12799639). A telephone replay of the conference call may be accessed through August 22, 2017 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 12799639). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com under the investors section and will be archived there until August 22, 2017.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs, and the benefits to be derived from NUPLAZID® (pimavanserin) and ACADIA’s product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization, and in collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2016 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Investor Relations